Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone801-438-1036
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40,000.00
Profitability
Miscellaneous
Employees22
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions
What is Co-Diagnostics' stock symbol?
Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."
How were Co-Diagnostics' earnings last quarter?
Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. The firm earned $0.06 million during the quarter. Co-Diagnostics had a negative net margin of 7,369.12% and a negative return on equity of 267.08%. View Co-Diagnostics' Earnings History.
When is Co-Diagnostics' next earnings date?
What price target have analysts set for CODX?
2 equities research analysts have issued 1-year price objectives for Co-Diagnostics' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Co-Diagnostics' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 94.2% from the stock's current price. View Analyst Price Targets for Co-Diagnostics.
What is the consensus analysts' recommendation for Co-Diagnostics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.
What are Wall Street analysts saying about Co-Diagnostics stock?
Here are some recent quotes from research analysts about Co-Diagnostics stock:
- 1. According to Zacks Investment Research, "Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. Co-Diagnostics Inc. is based in UT, United States. " (10/7/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is based on a comparable universe derived enterprise value-to-sales (EV/ Sales) multiple of 5.7x and projected sales of $0.36 per share for the next 12 months. Risks include, but are not limited to: (1) lower-than-projected uptake of products; (2) inability to maintain regulatory compliance; and (3) inability to develop additional products targeting segments beyond infectious disease in developing markets. Co-Diagnostics, Inc." (8/16/2019)
Has Co-Diagnostics been receiving favorable news coverage?
Headlines about CODX stock have trended neutral this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Co-Diagnostics earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Co-Diagnostics.
Are investors shorting Co-Diagnostics?
Co-Diagnostics saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 586,000 shares, a decline of 14.2% from the August 15th total of 683,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 0.5 days. Currently, 5.6% of the company's shares are sold short. View Co-Diagnostics' Current Options Chain.
Who are some of Co-Diagnostics' key competitors?
Some companies that are related to Co-Diagnostics include Spectral Medical (EDTXF), Endologix (ELGX), Apollo Endosurgery (APEN), Pro-Dex (PDEX), AIT Therapeutics (AITB), Motus GI (MOTS), STRATA Skin Sciences (SSKN), BeyondAirInc . (XAIR), Nephros (NEPHD), Invo Bioscience (IVOB), Arch Therapeutics (ARTH), SANUWAVE Health (SNWV), Interpace Diagnostics Group (IDXG), PAVmed (PAVM) and Nuvectra (NVTR).
What other stocks do shareholders of Co-Diagnostics own?
Who are Co-Diagnostics' key executives?
Co-Diagnostics' management team includes the folowing people:
- Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)
- Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)
- Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)
- Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
- Mr. Cameron Gundry, Head of Commercialization LATAM/EUR
When did Co-Diagnostics IPO?
(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.
How do I buy shares of Co-Diagnostics?
Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Co-Diagnostics' stock price today?
One share of CODX stock can currently be purchased for approximately $1.03.
How big of a company is Co-Diagnostics?
What is Co-Diagnostics' official website?
How can I contact Co-Diagnostics?
Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]
MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
